Ovarian Cancer Types ~ Ovarian Cancer — Risk / Phenotype

Specific ovarian cancer subtypes or pathologies associated with given genes/mutations

List was last updated on Dec 1, 2019 @ 8:08 am.


    • Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
    • Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Sci Rep. 2019 Nov 28;9(1):17808. doi: 10.1038/s41598-019-54116-y.
    • Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    • Ruiz de Sabando A, Urrutia Lafuente E, García-Amigot F, Alonso Sánchez A, Morales Garofalo L, Moreno S, Ardanaz E, Ramos-Arroyo MA.
    • BMC Cancer. 2019 Nov 27;19(1):1145. doi: 10.1186/s12885-019-6277-x.
    • Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    • Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM.
    • Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670-1. doi: 10.1016/j.ygyno.2019.11.019. [Epub ahead of print]
    • Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
    • Dowson CB, Stewart C, O'Sullivan S, Pachter N, Schofield L, Cohen PA.
    • Int J Gynecol Cancer. 2019 Nov 7. pii: ijgc-2019-000540. doi: 10.1136/ijgc-2019-000540. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    • Fragoso-Ontiveros V, Velázquez-Aragón JA, Nuñez-Martínez PM, de la Luz Mejía-Aguayo M, Vidal-Millán S, Pedroza-Torres A, Sánchez-Contreras Y, Ramírez-Otero MA, Muñiz-Mendoza R, Domínguez-Ortíz J, Wegman-Ostrosky T, Bargalló-Rocha JE, Gallardo-Rincón D, Reynoso-Noveron N, Arriaga-Canon C, Meneses-García A, Herrera-Montalvo LA, Alvarez-Gomez RM.
    • PLoS One. 2019 Sep 23;14(9):e0222709. doi: 10.1371/journal.pone.0222709. eCollection 2019.
    • Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    • Cheng A, Li L, Wu M, Lang J.
    • Eur J Surg Oncol. 2019 Sep 5. pii: S0748-7983(19)30662-6. doi: 10.1016/j.ejso.2019.09.002. [Epub ahead of print]
    • Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.
    • Colin C, Doutriaux-Dumoulin I.
    • Radiology. 2019 Sep 3:191306. doi: 10.1148/radiol.2019191306. [Epub ahead of print]
    • Letter, Comment

    Original research:

    BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

    • Inherited cancer syndromes in 220 Italian ovarian cancer patients.
    • Carnevali I, Riva C, Chiaravalli AM, Sahnane N, Di Lauro E, Viel A, Rovera F, Formenti G, Ghezzi F, Sessa F, Tibiletti MG.
    • Cancer Genet. 2019 Sep;237:55-62. doi: 10.1016/j.cancergen.2019.06.005. Epub 2019 Jun 12.
    • BRCA mutation in high grade epithelial ovarian cancers.
    • Manchana T, Phoolcharoen N, Tantbirojn P.
    • Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
    • Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
    • Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
    • Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
    • Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH.
    • Cancer Res Treat. 2019 Jul;51(3):941-950. doi: 10.4143/crt.2018.312. Epub 2018 Oct 8.
    • The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).
    • Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, Tsuda H, Watanabe Y, Yoshihara K, Sugiyama T.
    • Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384.
    • Fallopian Tube Carcinoma.
    • Stasenko M, Fillipova O, Tew WP.
    • J Oncol Pract. 2019 Jul;15(7):375-382. doi: 10.1200/JOP.18.00662. Epub 2019 Jul 8.

    Commentary:

    Rapidly Changing Landscape of Fallopian Tube Carcinoma.

    • BRCA germline mutation test for all woman with ovarian cancer?
    • Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I.
    • BMC Cancer. 2019 Jun 28;19(1):641. doi: 10.1186/s12885-019-5829-4.
    • Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    • Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.
    • Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Hereditary ovarian cancers: state of the art.
    • Toss A, Molinaro E, Sammarini M, Del Savio MC, Cortesi L, Facchinetti F, Grandi G.
    • Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.06091-9. [Epub ahead of print]
    • Review
    • Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
    • Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, Mackean M, Nussey F, Semple CA, Herrington CS, Gourley C.
    • Am J Obstet Gynecol. 2019 May 2. pii: S0002-9378(19)30620-9. doi: 10.1016/j.ajog.2019.04.035. [Epub ahead of print]
    • Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    • Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.
    • Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
    • BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
    • Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E.
    • Radiology. 2019 Apr 30:181814. doi: 10.1148/radiol.2019181814. [Epub ahead of print]

    Letter, Comment:

    Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.

    • Ovarian small cell carcinoma in one of a pair of monozygous twins.
    • Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, Foulkes WD.
    • Fam Cancer. 2019 Apr;18(2):161-163. doi: 10.1007/s10689-018-0108-0.
    • Letter, Case report
    • A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis.
    • Islam MJ, Roshid B, Pervin S, Kabir S, Chigurupati S, Hasan MN.
    • Mymensingh Med J. 2019 Apr;28(2):484-489.
    • Case report
    • Co-occurrence of Mayer-Rokitansky-Küster-Hauser syndrome and ovarian cancer: A case report and review of the literature.
    • Villa R, Azzollini J, Peissel B, Manoukian S.
    • Gynecol Oncol Rep. 2019 Mar 17;28:68-70. doi: 10.1016/j.gore.2019.03.010. eCollection 2019 May.
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Ovarian Clear Cell Carcinoma in Cowden Syndrome.
    • Yauy K, Imbert-Bouteille M, Bubien V, Lindet-Bourgeois C, Rathat G, Perrochia H, MacGrogan G, Longy M, Bessis D, Tinat J, Baert-Desurmont S, Blanluet M, Perre PV, Baudry K, Pujol P, Corsini C.
    • J Natl Compr Canc Netw. 2019 Jan;17(1):7-11. doi: 10.6004/jnccn.2018.7065.
    • Case report
    • Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    • Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.
    • Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.
    • Peutz-Jeghers Syndrome.
    • Wu M, Krishnamurthy K.
    • StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018-. 2018 Dec 17.
    • Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol.
    • Samimi G, Trabert B, Geczik AM, Duggan MA, Sherman ME.
    • JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061. doi: 10.1093/jncics/pky061. eCollection 2018 Oct.
    • Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA.
    • Yousif HM, Mohammed RA, Missawi HM, Elsawaf ZM, Albasri AM.
    • J Taibah Univ Med Sci. 2018 Dec 11;14(1):73-78. doi: 10.1016/j.jtumed.2018.11.005. eCollection 2019 Feb.
    • Germline pathogenic variants identified in women with ovarian tumors.
    • Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, Torene RI, McGill AK, Yackowski L, Murphy PD, Xu Z, Solomon BD, Klein RT, Hruska KS.
    • Gynecol Oncol. 2018 Dec;151(3):481-488. doi: 10.1016/j.ygyno.2018.09.030. Epub 2018 Oct 12.
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
    • Santana Dos Santos E, Lallemand F, Burke L, Stoppa-Lyonnet D, Brown M, Caputo SM, Rouleau E.
    • Cancers (Basel). 2018 Nov 16;10(11). pii: E453. doi: 10.3390/cancers10110453.
    • Cell Origins of High-Grade Serous Ovarian Cancer.
    • Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr.
    • Cancers (Basel). 2018 Nov 12;10(11). pii: E433. doi: 10.3390/cancers10110433.
    • Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    • Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.
    • Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.
    • Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted.
    • Benusiglio PR, Coulet F.
    • Gynecol Oncol Rep. 2018 Oct 12;26:69-70. doi: 10.1016/j.gore.2018.10.005. eCollection 2018 Nov.

    Original research:

    Characteristics of Lynch syndrome associated ovarian cancer.

    • Ovarian small cell carcinoma in one of a pair of monozygous twins.
    • Fahiminiya S, Sabbaghian N, Albrecht S, Nadaf J, Callegaro-Filho D, Foulkes WD.
    • Fam Cancer. 2018 Oct 4. doi: 10.1007/s10689-018-0108-0. [Epub ahead of print]
    • Case report
    • Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    • Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.
    • PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018.
    • Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
    • Sakurada S, Watanabe Y, Tokunaga H, Takahashi F, Yamada H, Takehara K, Yaegashi N.
    • Jpn J Clin Oncol. 2018 Sep 1;48(9):794-798. doi: 10.1093/jjco/hyy095.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study.
    • Lim MC, Won YJ, Lim J, Salehi T, Yoo CW, Bristow RE.
    • BMC Cancer. 2018 Aug 8;18(1):800. doi: 10.1186/s12885-018-4700-3.
    • Characteristics of Lynch syndrome associated ovarian cancer.
    • Woolderink JM, De Bock GH, de Hullu JA, Hollema H, Zweemer RP, Slangen BFM, Gaarenstroom KN, van Beurden M, van Doorn HC, Sijmons RH, Vasen HFA, Mourits MJE.
    • Gynecol Oncol. 2018 Aug;150(2):324-330. doi: 10.1016/j.ygyno.2018.03.060. Epub 2018 Jun 5.

    Letter, Commentary:

    Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted.

    • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
    • Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.
    • Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.
    • Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.
    • Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.
    • Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1358-1363. doi: 10.1158/1055-9965.EPI-18-0503. Epub 2018 Jul 17.
    • Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
    • Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube.
    • Choi MC, Bae JS, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim JH, Lee KC, Lee S, Lee JH.
    • J Gynecol Oncol. 2018 Jul;29(4):e43. doi: 10.3802/jgo.2018.29.e43. Epub 2018 Mar 26.
    • High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report.
    • Costella A, De Leo R, Guarino D, D'Indinosante M, Concolino P, Mazzuccato G, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Hum Genome Var. 2018 Jun 8;5:10. doi: 10.1038/s41439-018-0006-x. eCollection 2018.
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
    • Augustinsson A, Ellberg C, Kristoffersson U, Borg Å, Olsson H.
    • Acta Oncol. 2018 May;57(5):595-603. doi: 10.1080/0284186X.2017.1404635. Epub 2017 Nov 22.
    • Small cell cancers of the female genital tract: Molecular and clinical aspects.
    • Patibandla JR, Fehniger JE, Levine DA, Jelinic P.
    • Gynecol Oncol. 2018 May;149(2):420-427. doi: 10.1016/j.ygyno.2018.02.004. Epub 2018 Feb 17.
    • Review
    • Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China.
    • Sheng X, Zhong Y, Lu C, Peng J, Yu H, Guo J.
    • Int J Gynaecol Obstet. 2018 May;141(2):234-239. doi: 10.1002/ijgo.12447. Epub 2018 Feb 14.
    • BRCAmut and "founder effect": a prospective study in a single academic institution.
    • Loizzi V, Cicinelli E, Santamaria F, Murgia F, Minicucci V, Resta L, Resta N, Natalicchio MI, Ranieri G, Cormio G.
    • Oncotarget. 2018 Apr 27;9(32):22353-22358. doi: 10.18632/oncotarget.24959. eCollection 2018 Apr 27.
    • BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
    • Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.
    • Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.
    • The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    • Toptas T, Pestereli E, Simsek T, Bozkurt S, Erdogan G, Karaveli S.
    • J Cancer Res Ther. 2018 Apr-Jun;14(3):587-592. doi: 10.4103/0973-1482.172130.
    • [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.
    • Consensus statement, Review, [Article in Spanish]
    • Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    • Xiao X, Dong D, He W, Song L, Wang O, Yue J, Xie L.
    • Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.
    • Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    • Park KJ, Patel P, Linkov I, Jotwani A, Kauff N, Pike MC.
    • Histopathology. 2018 Apr;72(5):766-776. doi: 10.1111/his.13444. Epub 2018 Jan 29.
    • Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature.
    • Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K.
    • Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.
    • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    • Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.
    • BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    • Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans DG, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.
    • Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

    Press: Normal-tissue BRCA1 Methylation May Occur Before Birth, Raise Ovarian Cancer Risk. (Medscape/Reuters Health)

    Press: Commentary: Is This 'Provocative Finding' Related to Serous Ovarian Cancer? (Medscape Oncology)

    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective.
    • Dobrovic A.
    • Ann Intern Med. 2018 Mar 6;168(5):365-366. doi: 10.7326/M17-3340. Epub 2018 Jan 16.
    • Editorial
    • A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.
    • BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
    • Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
    • Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, Greene MH, Slangen BFM, van Beurden M, Massuger LFAG, Hoogerbrugge N, de Hullu JA.
    • Cancer. 2018 Mar 1;124(5):952-959. doi: 10.1002/cncr.31211. Epub 2018 Jan 9.

    Editorial:

    Who is at risk after risk reduction?

    • Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors.
    • Whynott RM, Manahan KJ, Geisler JP.
    • Am J Clin Oncol. 2018 Mar;41(3):286-288. doi: 10.1097/COC.0000000000000266.
    • Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.
    • Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
    • Gurda GT, Serdy KM, Yatsenko SA, Rajkovic A, Carter NJ, Ahmed R, Olawaiye AB, Bhargava R, Elishaev E.
    • Int J Gynecol Pathol. 2018 Mar;37(2):117-122. doi: 10.1097/PGP.0000000000000392.
    • MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
    • Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.
    • Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.
    • Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    • Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM.
    • Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.
    • Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    • Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.
    • Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.
    • [Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
    • Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.
    • Ned Tijdschr Geneeskd. 2018;162(0):D2337.
    • Case report, [Article in Dutch]
    • Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
    • Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.
    • Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.
    • Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression.
    • Harris HR, Rice MS, Shafrir AL, Poole EM, Gupta M, Hecht JL, Terry KL, Tworoger SS.
    • Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):96-102. doi: 10.1158/1055-9965.EPI-17-0609. Epub 2017 Nov 13.
    • Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.
    • Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H, Aoki D.
    • Oncotarget. 2017 Nov 28;8(68):112258-112267. doi: 10.18632/oncotarget.22733. eCollection 2017 Dec 22.
    • Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
    • Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.
    • JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.
    • Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    • Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA.
    • Gynecol Oncol. 2017 Dec;147(3):705-713. doi: 10.1016/j.ygyno.2017.10.001. Epub 2017 Oct 18.
    • Review
    • High grade serous ovarian carcinomas originate in the fallopian tube.
    • Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.
    • Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.
    • The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
    • Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, Li N, Bu H, Feng Y, Li Q, Lu X, Wei J, Zhu X, Mills J, Ellison G, Gutjahr T, Liu Y.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657. doi: 10.1097/IGC.0000000000001065.
    • Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    • Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.
    • Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary.
    • Huepenbecker SP, Divine L, Chu CS, Mutch DG.
    • Gynecol Oncol Rep. 2017 Sep 7;22:13-15. doi: 10.1016/j.gore.2017.09.002. eCollection 2017 Nov.
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • High-grade serous carcinoma of tubo-ovarian origin: recent developments.
    • Singh N, McCluggage WG, Gilks CB.
    • Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
    • Review
    • Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    • Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G, Korach J.
    • J Gynecol Oncol. 2017 Sep;28(5):e61. doi: 10.3802/jgo.2017.28.e61. Epub 2017 Jun 5.
    • Malignant Brenner tumor associated with a germline BRCA2 mutation.
    • Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA.
    • Gynecol Oncol Rep. 2017 May 31;21:17-19. doi: 10.1016/j.gore.2017.05.006. eCollection 2017 Aug.
    • Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
    • DeLeonardis K, Sedgwick K, Voznesensky O, Matloff E, Hofstatter E, Balk S, Tung N.
    • Breast J. 2017 Jul;23(4):461-464. doi: 10.1111/tbj.12764. Epub 2017 Jan 31.
    • Case report
    • The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
    • Witkowski L, Donini N, Byler-Dann R, Knost JA, Albrecht S, Berchuck A, McCluggage WG, Hasselblatt M, Foulkes WD.
    • Fam Cancer. 2017 Jul;16(3):395-399. doi: 10.1007/s10689-016-9957-6.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. [Presented Friday, June 2, 2017.] 2017;37:443-448. doi: 10.14694/EDBK_174718.
    • Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity.
    • Neuhausen SL, Shani H, Boker LK, Steele L, Silverman BG, Ottini L, Silvestri V, Laitman Y, Korach J, Perri T, Friedman E.
    • Anticancer Res. 2017 Jun;37(6):3069-3072.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):443-448. doi: 10.1200/EDBK_174718.
    • Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    • Begg CB, Rice MS, Zabor EC, Tworoger SS.
    • Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    • Hjortkjær M, Waldstrøm M, Jakobsen A, Kanstrup H, Søgaard-Andersen E, Dahl Steffensen K.
    • Int J Gynecol Pathol. 2017 Mar;36(2):180-189. doi: 10.1097/PGP.0000000000000310.
    • Genetics and Genomics of Ovarian Sex Cord-Stromal Tumors.
    • Fuller PJ, Leung D, Chu S.
    • Clin Genet. 2017 Feb;91(2):285-291. doi: 10.1111/cge.12917.
    • Review
    • [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis].
    • Tao T, Yang JX, Shen K, Cao DY.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):20-25. doi: 10.3760/cma.j.issn.0529-567X.2017.01.006.
    • Article in Chinese; English Abstract
    • Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes.
    • Carnevali IW, Cimetti L, Sahnane N, Libera L, Cavallero A, Formenti G, Riva C, Tibiletti MG.
    • Int J Gynecol Pathol. 2017 Jan;36(1):64-70. doi: 10.1097/PGP.0000000000000290.
    • Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    • Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.
    • J Gynecol Oncol. 2017 Jan;28(1):e3. doi: 10.3802/jgo.2017.28.e3. Epub 2016 Aug 8.
    • Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    • Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH, Liou JD, Chen SJ, Wang TH, Lai CH.
    • Oncotarget. 2016 Dec 20;7(51):85529-85541. doi: 10.18632/oncotarget.13456.
    • Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    • Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.
    • Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.
    • Review
    • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
    • Weinberger V, Bednarikova M, Cibula D, Zikan M.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. Epub 2016 Oct 22.
    • Review
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.
    • Seidman JD, Krishnan J, Yemelyanova A, Vang R.
    • Int J Gynecol Pathol. 2016 Sep;35(5):423-429.
    • Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient.
    • Kahn R, Garcia-Soto A, Silva-Smith R, Pinto A, George SH.
    • Gynecol Oncol Rep. 2016 Aug 2;17:93-5. doi: 10.1016/j.gore.2016.08.001. eCollection 2016.
    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    • Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.
    • Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.
    • Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
    • Casey MJ, Colanta AB.
    • Fam Cancer. 2016 Jul;15(3):371-84. doi: 10.1007/s10689-016-9878-4.
    • Review
    • Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment.
    • Foulkes WD, Gore M, McCluggage WG.
    • Gynecol Oncol. 2016 Jul;142(1):190-8. doi: 10.1016/j.ygyno.2016.04.005. Epub 2016 Apr 19.
    • Review
    • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
    • Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJ, Hendricks WP, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, Foulkes WD.
    • Gynecol Oncol. 2016 Jun;141(3):454-60. doi: 10.1016/j.ygyno.2016.03.013. Epub 2016 Mar 19.
    • Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.
    • Iavazzo C, Gkegkes ID, Vrachnis N.
    • J Turk Ger Gynecol Assoc. 2016 Jan 12;17(2):73-6. doi: 10.5152/jtgga.2016.15223. eCollection [2016 Jun;].
    • Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
    • Malmberg K, Klynning C, Flöter-Rådestad A, Carlson JW.
    • Virchows Arch. 2016 Jun;468(6):707-13. doi: 10.1007/s00428-016-1928-7. Epub 2016 Mar 22.
    • Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
    • Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, Ponzone R, Pasini B.
    • Ecancermedicalscience. 2016 May 3;10:639. doi: 10.3332/ecancer.2016.639. eCollection 2016.
    • The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
    • Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.
    • Arch Gynecol Obstet. 2016 Apr;293(4):695-700. doi: 10.1007/s00404-016-4035-8. Epub 2016 Feb 19.
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    • Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
    • Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
    • Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    • Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.
    • Am J Surg Pathol. 2016 Mar;40(3):404-9. doi: 10.1097/PAS.0000000000000556.
    • Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    • Chay WY, McCluggage WG, Lee CH, Köbel M, Irving J, Millar J, Gilks CB, Tinker AV.
    • Int J Gynecol Cancer. 2016 Mar;26(3):431-6. doi: 10.1097/IGC.0000000000000639.
    • BRCA2-positive spinal intramedullary ovarian metastatic disease: case report.
    • Ravindra VM, Mazur MD, Driscoll M, McEvoy S, Schmidt MH.
    • Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.
    • Case report
    • Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers.
    • Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, Segev Y.
    • Int J Gynecol Cancer. 2016 Feb;26(2):233-9. doi: 10.1097/IGC.0000000000000624.
    • Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer.
    • Szatkowski W, Blecharz P, Mituś JW, Jasiówka M, Łuczyńska E, Jakubowicz J, Byrski T.
    • Hered Cancer Clin Pract. 2016 Jan 23;14:4. doi: 10.1186/s13053-015-0041-2. eCollection 2016.
    • It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research.
    • Perets R, Drapkin R.
    • Cancer Res. 2016 Jan 1;76(1):10-7. doi: 10.1158/0008-5472.CAN-15-1382. Epub 2015 Dec 15.
    • Review
    • Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry.
    • Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA.
    • Fam Cancer. 2016 Jan;15(1):105-10. doi: 10.1007/s10689-015-9831-y.
    • Case report
    • Rare primary fallopian tube carcinoma; a gynaecologist's dilemma.
    • Chaudhry S, Hussain R, Zuberi MM, Zaidi Z.
    • J Pak Med Assoc. 2016 Jan;66(1):107-10.
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • Do hereditary syndrome-related gynecologic cancers have any specific features?
    • Neto N, Cunha TM.
    • Insights Imaging. 2015 Oct;6(5):545-52. doi: 10.1007/s13244-015-0425-x. Epub 2015 Sep 4.
    • Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series.
    • Matsuo K, Tierney KE, Schneider DM, Mhawech-Fauceglia P, Roman LD, Gershenson DM.
    • Gynecol Oncol Rep. 2015 Jun 11;13:36-9. doi: 10.1016/j.gore.2015.06.003. eCollection 2015.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Ovarian Tumor of LMP

    • Ovarian microcystic stromal tumor: A novel extracolonic tumor in familial adenomatous polyposis.
    • Lee SH, Koh YW, Roh HJ, Cha HJ, Kwon YS.
    • Genes Chromosomes Cancer. 2015 Jun;54(6):353-60. doi: 10.1002/gcc.22233. Epub 2015 Mar 28.
    • Case report
    • Ovarian carcinoma in a 14-year-old with classical salt-wasting congenital adrenal hyperplasia and bilateral adrenalectomy.
    • Pina C, Khattab A, Katzman P, Bruckner L, Andolina J, New M, Yau M.
    • J Pediatr Endocrinol Metab. 2015 May 1;28(5-6):663-7. doi: 10.1515/jpem-2014-0299.
    • Case report
    • Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    • Rauh-Hain JA, Foley OW, Winograd D, Andrade C, Clark RM, Vargas RJ, Hinchcliff EM, Esselen KM, Horowitz NS, del Carmen MG.
    • Am J Obstet Gynecol. 2015 May;212(5):600.e1-8. doi: 10.1016/j.ajog.2014.12.013. Epub 2014 Dec 13.
    • Ovarian cancer survival by tumor dominance, a surrogate for site of origin.
    • Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J.
    • Cancer Causes Control. 2015 Apr;26(4):601-8. doi: 10.1007/s10552-015-0547-y. Epub 2015 Mar 13.
    • Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review.
    • Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK.
    • Gynecol Oncol. 2015 Mar;136(3):571-581. doi: 10.1016/j.ygyno.2015.01.534. Epub 2015 Jan 20.
    • Review
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.
    • Dubeau L.
    • Transl Cancer Res. 2015 Feb;4(1):3-13.
    • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    • Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.
    • Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.
    • A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    • Cass I, Walts AE, Barbuto D, Lester J, Karlan B.
    • Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
    • Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.
    • Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK.
    • Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.
    • Letter
    • Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
    • Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.
    • Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.
    • Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.
    • Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.
    • Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.
    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.
    • Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry.
    • Park JM, Kim MK.
    • J Menopausal Med. 2014 Apr;20(1):14-20. doi: 10.6118/jmm.2014.20.1.14. Epub 2014 Apr 28.
    • Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.
    • Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, Wei JJ, Zhang ZH, Liu J.
    • Int J Clin Exp Pathol. 2014 Feb 15;7(3):848-57. eCollection 2014.
    • Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
    • Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL.
    • Sci Rep. 2014 Feb 7;4:4026. doi: 10.1038/srep04026.
    • Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube.
    • Dietl J.
    • Arch Gynecol Obstet. 2014 Feb;289(2):241-6. doi: 10.1007/s00404-013-3041-3. Epub 2013 Oct 8.
    • Review
    • The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    • Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.
    • Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    • Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P.
    • Fam Cancer. 2013 Dec;12(4):719-40. doi: 10.1007/s10689-013-9651-x.
    • [Pathologic features of BRCA-associated ovarian carcinoma].
    • Guo DH, Zheng WX.
    • Zhonghua Bing Li Xue Za Zhi. 2013 Dec;42(12):846-50.
    • [Article in Chinese]
    • The role of the fallopian tube in the origin of ovarian cancer.
    • Erickson BK, Conner MG, Landen CN Jr.
    • Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.

    Letter, Comment:

    Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.

    Letter, Reply:

    Reply: To PMID 23583217.

    • Added value of family history in counseling about risk of BRCA1/2 mutation in early-onset epithelial ovarian cancer.
    • Arts-de Jong M, Manders CM, Hoogerbrugge N, Ligtenberg MJ, Massuger LF, de Hullu JA, Spruijt L.
    • Int J Gynecol Cancer. 2013 Oct;23(8):1406-10. doi: 10.1097/IGC.0b013e3182a1cf71.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    • Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C.
    • Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29.
    • Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    • George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G, Bowtell DD.
    • Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.

    Research news:

    Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.

    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527.

    Retraction:

    Retraction.

    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • In vitro fertilization is associated with an increased risk of borderline ovarian tumours.
    • Stewart LM, Holman CD, Finn JC, Preen DB, Hart R.
    • Gynecol Oncol. 2013 May;129(2):372-6. doi: 10.1016/j.ygyno.2013.01.027. Epub 2013 Feb 4.
    • Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    • Reitsma W, Mourits MJ, de Bock GH, Hollema H.
    • Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.
    • Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
    • Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M; PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Anne Rossing M, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Mat Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Krüger Kjaer S, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA; stralian Ovarian Cancer Study Group; stralian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Leigh Pearce C.
    • Nat Commun. 2013 Mar 27;4:1628. doi: 10.1038/ncomms2629.

    Press: Risk Of Ovarian Cancer Increased By 5 Genetic Variations. (Medical News Today)

    • Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.
    • Băltătescu GI, Așchie M, Sârbu V.
    • Chirurgia (Bucur). 2013 Mar-Apr;108(2):259-63.
    • Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
    • Köbel M, Ghatage P.
    • Int J Gynecol Pathol. 2013 Mar;32(2):176. doi: 10.1097/PGP.0b013e31826b4ea1.
    • Comment, Letter

    Case report:

    A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.

    Letter, Reply:

    In reply.

    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Increased incidence of brain metastases in BRCA1-related ovarian cancers.
    • Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K.
    • J Obstet Gynaecol Res. 2013 Jan;39(1):292-6. doi: 10.1111/j.1447-0756.2012.01961.x. Epub 2012 Aug 13.
    • Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).
    • Delair D, Soslow RA.
    • Histopathology. 2012 Sep;61(3):329-39. doi: 10.1111/j.1365-2559.2011.04167.x. Epub 2012 Feb 28.
    • Review
    • Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
    • Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.
    • Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.
    • Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    • Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN.
    • Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40. doi: 10.1097/AOG.0b013e31825f3576.

    Editorial:

    Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore.

    • BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    • Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.
    • J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18.

    Press: Routine BRCA Mutation Testing Urged in Ovarian Cancer. (Medscape/Reuters Health)

    • Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    • Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.
    • Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.
    • A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
    • Maurac I, Sabol M, Musani V, Car D, Ozretic P, Kalafatic D, Oreskovic S, Babic D, Levanat S.
    • Int J Gynecol Pathol. 2012 May;31(3):264-71. doi: 10.1097/PGP.0b013e31823b6f0f.
    • Case Report

    Comment, Letter:

    Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.

    • Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
    • Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A; Ovarian Cancer Association Consortium.
    • Lancet Oncol. 2012 Apr;13(4):385-94. doi: 10.1016/S1470-2045(11)70404-1. Epub 2012 Feb 22.

    Comment:

    Gynecological cancer: Endometriosis link to invasive subtypes.

    Comment:

    Link between endometriosis and ovarian-cancer subtypes.

    Comment, Letter:

    Endometriosis and ovarian cancer.

    Comment, Letter:

    Endometriosis and ovarian cancer.

    Press: Endometriosis Linked to Certain Subtypes of Ovarian Cancer. (Medscape)

    Press: Endometriosis is associated with an increased risk of ovarian cancer, study shows. (BMJ)

    • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    • Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.
    • Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.
    • High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    • Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, Osuch B, Markowska J, Bidzinski M, Kupryjanczyk J.
    • Cancer Genet. 2012 Mar;205(3):94-100. doi: 10.1016/j.cancergen.2011.12.005.
    • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    • Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
    • Bilyk EA, Buchanskaia LG, Polishchuk LZ, Peëvich T.
    • Vopr Onkol. 2012;58(4):507-13.
    • [Article in Russian]